Get to know the once-weekly Wegovy^® pen

One and done 
Single-use pen that patients dispose of after one use¹

No dose dialing
Patients administer a preset dose for accurate dose delivery¹

Autoinjector with an integrated 29G needle
Patients will not need to see or handle a needle¹

Dose-escalation schedule: Start your patients at the 0.25 mg once-weekly dose and follow the dose-escalation schedule. See the Wegovy^® Prescribing Information for details.¹

• If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks
• The maintenance dose of Wegovy^® in adults is either 2.4 mg (recommended) or 1.7 mg once weekly. Consider treatment response and tolerability when selecting the maintenance dose
• If adolescent patients do not tolerate the 2.4 mg once-weekly maintenance dosage, the maintenance dosage may be reduced to 1.7 mg once weekly. Discontinue Wegovy^® if the patient cannot tolerate the 1.7 mg once-weekly dosage
  

(2:09)

Review the complete Instructions for Use.

Learn how to properly use the Wegovy^® pen

Watch this short video to understand how best to train your patients to administer Wegovy^®.

Wegovy^® administration¹

Patients should administer Wegovy^® once weekly, on the same day each week, at any time of day, with or without meals. Wegovy^® can be administered any time of day.

Wegovy^® should be injected subcutaneously in the abdomen, thigh, or upper arm. Patients can rotate the injection site each time.

Administration tips¹

The injection will take ~10 seconds, during which patients will hear 2 clicks. Direct them to press the pen firmly for the entire injection and not to remove the pen until the yellow bar has stopped moving.

If they have problems injecting, change to a firmer injection site, such as upper leg or upper arm, or consider standing up while injecting into the lower stomach.

If medicine appears on the skin or leaks during injection, during the next injection, instruct patients to keep applying pressure until the yellow bar has stopped moving.

Dose-Escalation Schedule

Dosing designed with your patients in mind¹

Gradual Wegovy^® dose escalation gives patients time to adjust to treatment

Dose-escalation schedule

Start your patients with once-weekly Wegovy^® at 0.25 mg and escalate the dose every 4 weeks.

Follow the dose-escalation schedule to reduce the risk of gastrointestinal adverse reactions.¹

Injected subcutaneously once weekly.

What to do if patients…

Need additional time to adjust to Wegovy^®1:

If patients do not tolerate a dose during dose escalation:

Consider delaying dose escalation for 4 weeks.

Miss dose(s) of Wegovy^®1:

Patients miss 1 dose and the next dose is:

>2 days (48 hours): Instruct them to administer Wegovy^® as soon as possible.
<2 days (48 hours): Inform them to NOT administer a dose of Wegovy^®. Resume dosing on the regularly scheduled day of the week.

Patients miss 2 or more consecutive doses:

Inform them to resume dosing as scheduled. Or if needed, inform them to reinitiate Wegovy^® and follow the dose-escalation schedule, which may reduce the occurrence of GI symptoms associated with reinitiation of treatment.

GI, gastrointestinal.

Every patient is different. Here are some general considerations for helping your patients manage nausea^2,3

Eat bland, low-fat foods such as crackers,
toast, and rice

Don’t lie down after you eat

Go outside and get some fresh air

Eat foods that contain water, such as soup and gelatin

Eat more slowly    

Specific Populations and Drug Interactions¹

Patients taking oral contraceptives*

No clinically relevant drug-drug interaction was observed when an oral contraceptive drug was given with semaglutide 1 mg at steady state.¹*

Due to a delay in gastric emptying, caution must be exercised when any oral medications are given along with Wegovy^®.

Because of the potential for fetal harm, discontinue Wegovy^® in people at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide.

*A drug-interaction study evaluated the potential impact of semaglutide 1 mg at steady state on the exposure of a co-administered combined oral contraceptive ethinyl estradiol/levonorgestrel at steady state.¹

Patients taking an insulin or insulin secretagogue (eg, sulfonylurea)

Wegovy^® lowers blood glucose and can cause hypoglycemia. The addition of Wegovy^® in patients treated with insulin has not been evaluated. When initiating Wegovy^®, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.¹

Patients taking oral medications

Wegovy^® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy^®.¹

References

1. Wegovy^® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.

2. MedlinePlus. When you have nausea and vomiting. MedlinePlus website. Accessed March 21, 2024. https://medlineplus.gov/ency/patientinstructions/000122.htm

3. Cleveland Clinic. Nausea and vomiting. Cleveland Clinic website. Accessed March 21, 2024. https://my.clevelandclinic.org/health/symptoms/8106-nausea–vomiting